翰森製藥(03692.HK)獨家負責希維奧在中國商業化
翰森製藥(03692.HK)公布,其全資附屬江蘇豪森藥業集團與德琪醫藥(06996.HK)訂立獨家合作協議。集團將獨家負責塞利尼索(selinexor)及任何包含或由塞利尼索組成的產品(商品名:希維奧)在中國的商業化,德琪醫藥將繼續負責希維奧(塞利尼索)的研發、監管審批事務、產品供應和分銷。
德琪醫藥將獲得最高可達2億元人民幣(下同)的首付款,其中1億元於簽約時支付,並根據協議及其條款和條件,德琪醫藥將有可能獲得最高可達1億元的剩餘首付款,以及最高可達5.35億元的里程碑付款。此外,德琪醫藥還將向集團支付服務費。
希維奧(塞利尼索)是全球首個全新機制的口服選擇性核輸出蛋白抑制劑,其被開發用於治療多種血液系統惡性腫瘤及實體瘤。截至目前,希維奧(塞利尼索)已在中國獲批用於聯合地塞米松用於治療既往接受過治療且對至少一種蛋白(酉每)體抑制劑、一種免疫調節劑以及一種抗CD38單克隆抗體藥物難治的復發/難治性多發性骨髓瘤成人患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.